

AMENDMENT

Subject matter to be added is in bold and underlined.

Subject matter to be deleted is in bold and strikethrough.

In the Claims:


Please enter rewritten claims 1-7 and 10 and new claims 11-22 as follows.

Please cancel claim 9 without prejudice.

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A compound of formula I:



I

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

A is selected from $-\text{COR}^5$, $-\text{CO}_2\text{H}$, $\text{CH}_2\text{CO}_2\text{H}$, $-\text{CO}_2\text{R}^6$, $-\text{CONHOH}$, $-\text{CONHOR}^5$, $-\text{CONHOR}^6$, $-\text{N}(\text{OH})\text{COR}^5$, $-\text{N}(\text{OH})\text{CHO}$, $-\text{SH}$, $-\text{CH}_2\text{SH}$, $-\text{S}(\text{O})(=\text{NH})\text{R}^{\text{a}}$, $-\text{SN}_2\text{H}_2\text{R}^{\text{a}}$, $-\text{PO}(\text{OH})_2$, and $-\text{PO}(\text{OH})\text{NHR}^{\text{a}}$;

ring B is a 3-13 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-3 carbonyl groups, 0-4 double bonds, and from 0-2 ring

~~heteroatoms selected from O, N, NR², and S(O)_p, provided that ring B contains other than a S-S, O-O, or S-O bond piperidinyl or pyridinyl;~~

Z is ~~absent or selected from a C₃₋₁₃ carbocycle phenyl substituted with 0-4 R^b, naphthyl substituted with 0-5 R^b, and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or tetrahydronaphthyl~~ substituted with 0-5 R^b;

U^a is absent or is selected from: O, NR^{a1}, C(O), C(O)O, OC(O), C(O)NR^{a1}, NR^{a1}C(O), OC(O)O, OC(O)NR^{a1}, NR^{a1}C(O)O, NR^{a1}C(O)NR^{a1}, S(O)_p, S(O)_pNR^{a1}, NR^{a1}S(O)_p, and NR^{a1}SO₂NR^{a1};

X^a is absent or selected from C₁₋₁₀ alkylene, C₂₋₁₀ alkenylene, and C₂₋₁₀ alkynylene;

Y^a is absent or selected from O, NR^{a1}, S(O)_p, and C(O);

Z^a is ~~selected from H, a C₃₋₁₃ carbocycle pyridyl substituted with 0-5 0-4 R^c and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or quinolinyl~~ substituted with 0-5 R^c;

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

R^2 is selected from Q, Cl, F, C₁₋₁₀ alkylene-Q substituted with 0-3 R^{b1} , C₂₋₁₀ alkenylene-Q substituted with 0-3 R^{b1} , C₂₋₁₀ alkynylene-Q substituted with 0-3 R^{b1} ,
 $(CR^aR^{a1})_r^1O(CR^aR^{a1})_r^1-Q$, $(CR^aR^{a1})_r^1NR^a(CR^aR^{a1})_r^1-Q$, $(CR^aR^{a1})_r^1C(O)(CR^aR^{a1})_r^1-Q$,
 $(CR^aR^{a1})_r^1C(O)O(CR^aR^{a1})_r^1-Q$, $(CR^aR^{a1})_r^1C(O)O-C_{2-5}$ alkenylene, $(CR^aR^{a1})_r^1C(O)O-C_{2-5}$ alkynylene, $(CR^aR^{a1})_r^1OC(O)(CR^aR^{a1})_r^1-Q$, $(CR^aR^{a1})_r^1C(O)NR^aR^{a1}$,
 $(CR^aR^{a1})_r^1C(O)NR^a(CR^aR^{a1})_r^1-Q$, $(CR^aR^{a1})_r^1NR^aC(O)(CR^aR^{a1})_r^1-Q$,
 $(CR^aR^{a1})_r^1OC(O)O(CR^aR^{a1})_r^1-Q$, $(CR^aR^{a1})_r^1OC(O)NR^a(CR^aR^{a1})_r^1-Q$,
 $(CR^aR^{a1})_r^1NR^aC(O)O(CR^aR^{a1})_r^1-Q$, $(CR^aR^{a1})_r^1NR^aC(O)NR^a(CR^aR^{a1})_r^1-Q$,
 $(CR^aR^{a1})_r^1S(O)_p(CR^aR^{a1})_r^1-Q$, $(CR^aR^{a1})_r^1SO_2NR^a(CR^aR^{a1})_r^1-Q$,
 $(CR^aR^{a1})_r^1NR^aSO_2(CR^aR^{a1})_r^1-Q$, and $(CR^aR^{a1})_r^1NR^aSO_2NR^a(CR^aR^{a1})_r^1-Q$;

R^{2a} is selected from H, C₁₋₆ alkyl, OR^a, NR^aR^{a1}, and S(O)_pR^a;

R^{2b} is H or C₁₋₆ alkyl;

Q is selected from H, and a C₃₋₁₃ carbocycle substituted with 0-5 R^d ~~and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-5 R^d~~;

R^3 is selected from Q¹, Cl, F, C₁₋₆ alkylene-Q¹, C₂₋₆ alkenylene-Q¹, C₂₋₆ alkynylene-Q¹,
 $(CR^aR^{a1})_r^1O(CR^aR^{a1})_r^1-Q^1$, $(CR^aR^{a1})_r^1NR^a(CR^aR^{a1})_r^1-Q^1$,
 $(CR^aR^{a1})_r^1NR^aC(O)(CR^aR^{a1})_r^1-Q^1$, $(CR^aR^{a1})_r^1C(O)NR^a(CR^aR^{a1})_r^1-Q^1$,
 $(CR^aR^{a1})_r^1C(O)(CR^aR^{a1})_r^1-Q^1$, $(CR^aR^{a1})_r^1C(O)O(CR^aR^{a1})_r^1-Q^1$,
 $(CR^aR^{a1})_2r^1S(O)_p(CR^aR^{a1})_r^1-Q^1$, and $(CR^aR^{a1})_r^1SO_2NR^a(CR^aR^{a1})_r^1-Q^1$;

Q¹ is selected from H, phenyl substituted with 0-3 R^d, and naphthyl substituted with 0-3 R^d ~~and a 5-10 membered heteroaryl comprising: carbon atoms and 1-4~~

~~heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^d;~~

R^a, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

R^{a1}, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

alternatively, R^a and R^{a1} when attached to a nitrogen are taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and from 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)_p;

R^{a2}, at each occurrence, is independently selected from C₁₋₄ alkyl, phenyl and benzyl;

R^b, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, I, =O, -CN, NO₂, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, R^aNC(O)NR^aR^{a1}, OC(O)NR^aR^{a1}, R^aNC(O)O, S(O)₂NR^aR^{a1}, NR^aS(O)₂R^{a2}, NR^aS(O)₂NR^aR^{a1}, OS(O)₂NR^aR^{a1}, NR^aS(O)₂R^{a2}, S(O)_pR^{a2}, CF₃, and CF₂CF₃;

R^{b1}, at each occurrence, is independently selected from OR^a, Cl, F, Br, I, =O, -CN, NO₂, and NR^aR^{a1};

R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, I, =O, -CN, NO₂, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, R^aNC(O)NR^aR^{a1}, OC(O)NR^aR^{a1}, R^aNC(O)O, S(O)₂NR^aR^{a1}, NR^aS(O)₂R^{a2}, NR^aS(O)₂NR^aR^{a1}, OS(O)₂NR^aR^{a1}, NR^aS(O)₂R^{a2}, S(O)_pR^{a2}, CF₃, CF₂CF₃, and C₃₋₁₀ carbocycle substituted with 0-3 R^{c1} and a 5-14 membered heterocycle comprising: carbon atoms and 1-4

~~heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^{e1};~~

R^{c1}, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, I, =O, -CN, NO₂, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, R^aNC(O)NR^aR^{a1}, OC(O)NR^aR^{a1}, R^aNC(O)O, S(O)₂NR^aR^{a1}, NR^aS(O)₂R^{a2}, NR^aS(O)₂NR^aR^{a1}, OS(O)₂NR^aR^{a1}, NR^aS(O)₂R^{a2}, S(O)_pR^{a2}, CF₃, and CF₂CF₃;

R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, I, =O, -CN, NO₂, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, R^aNC(O)NR^aR^{a1}, OC(O)NR^aR^{a1}, R^aNC(O)O, S(O)₂NR^aR^{a1}, NR^aS(O)₂R^{a2}, NR^aS(O)₂NR^aR^{a1}, OS(O)₂NR^aR^{a1}, NR^aS(O)₂R^{a2}, S(O)_pR^{a2}, CF₃, CF₂CF₃, and C₃₋₁₀ carbocycle ~~and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p~~;

R⁵, at each occurrence, is selected from C₁₋₁₀ alkyl substituted with 0-2 R^b, and C₁₋₈ alkyl substituted with 0-2 R^e;

R^e, at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b;

R⁶, at each occurrence, is selected from phenyl, naphthyl, C₁₋₁₀ alkyl-phenyl-C₁₋₆ alkyl-, C₃₋₁₁ cycloalkyl, C₁₋₆ alkylcarbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxy carbonyloxy-C₁₋₃ alkyl-, C₂₋₁₀ alkoxy carbonyl, C₃₋₆ cycloalkylcarbonyloxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxycarbonyloxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxycarbonyl, phenoxy carbonyl, phenoxy carbonyloxy-C₁₋₃ alkyl-, phenyl carbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxy-C₁₋₆ alkylcarbonyloxy-C₁₋₃ alkyl-, [5-(C_{1-C5}

alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl,
[5-(R^a)-1,3-dioxa-cyclopenten-2-one-yl]methyl,
(5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, -C₁₋₁₀ alkyl-NR⁷R^{7a},
-CH(R⁸)OC(=O)R⁹, and -CH(R⁸)OC(=O)OR⁹;

R⁷ is selected from H and C₁₋₁₀ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl-, and phenyl-C₁₋₆ alkyl-;

R^{7a} is selected from H and C₁₋₁₀ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl-, and phenyl-C₁₋₆ alkyl-;

R⁸ is selected from H and C₁₋₄ linear alkyl;

R⁹ is selected from H, C₁₋₈ alkyl substituted with 1-2 R^f, C₃₋₈ cycloalkyl substituted with 1-2 R^f, and phenyl substituted with 0-2 R^b;


R^f, at each occurrence, is selected from C₁₋₄ alkyl, C₃₋₈ cycloalkyl, C₁₋₅ alkoxy, and phenyl substituted with 0-2 R^b;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

r¹, at each occurrence, is selected from 0, 1, 2, 3, and 4.

2. (Currently amended) A compound according to Claim 1, wherein the compound is of formula II:



II

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

A is selected from -CO₂H, CH₂CO₂H, -CONHOH, -CONHOR⁵, -CONHOR⁶,
-N(OH)COR⁵, -N(OH)CHO, -SH, and -CH₂SH;

ring B is ~~a 4-7 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, and NR², provided that ring B contains other than a O-O bond piperidinyl or pyridinyl;~~

Z is ~~absent or selected from a C₃₋₁₁ carbocycle phenyl substituted with 0-4 R^b, naphthyl substituted with 0-4 R^b, and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or tetrahydronaphthyl substituted with 0-4 0-3 R^b;~~

U^a is absent or is selected from: O, NR^{a1}, C(O), C(O)O, C(O)NR^{a1}, NR^{a1}C(O), S(O)_p, and S(O)_pNR^{a1};

X^a is absent or selected from C₁₋₄ alkylene, C₂₋₄ alkenylene, and C₂₋₄ alkynylene;

Y^a is absent or selected from O and NR^{a1};

~~Z^a is selected from H, a C₃₋₁₀ carbocycle pyridyl substituted with 0-5 0-4 R^c and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or quinolinyl substituted with 0-5 R^c;~~

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

R² is selected from Q, C₁₋₆ alkylene-Q, C₂₋₆ alkenylene-Q, C₂₋₆ alkynylene-Q, (CR^aR^{a¹})_{r¹}O(CR^aR^{a¹})_{r¹}-Q, (CR^aR^{a¹})_{r¹}NR^a(CR^aR^{a¹})_{r¹}-Q, (CR^aR^{a¹})_{r¹}C(O)(CR^aR^{a¹})_{r¹}-Q, (CR^aR^{a¹})_{r¹}C(O)O(CR^aR^{a¹})_{r¹}-Q, (CR^aR^{a¹})_{r¹}C(O)NR^aR^{a¹}, (CR^aR^{a¹})_{r¹}C(O)NR^a(CR^aR^{a¹})_{r¹}-Q, (CR^aR^{a¹})_{r¹}S(O)_p(CR^aR^{a¹})_{r¹}-Q, and (CR^aR^{a¹})_{r¹}SO₂NR^a(CR^aR^{a¹})_{r¹}-Q;

Q is selected from H, and a C₃₋₆ carbocycle substituted with 0-5 R^d, ~~and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-5 R^d~~;

R^a, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

R^{a¹}, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

alternatively, R^a and R^{a¹} when attached to a nitrogen are taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and

from 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)_p;

R^a², at each occurrence, is independently selected from C₁₋₄ alkyl, phenyl and benzyl;

R^b, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^a¹, C(O)R^a, C(O)OR^a, C(O)NR^aR^a¹, S(O)₂NR^aR^a¹, S(O)_pR^a², and CF₃;

R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^a¹, C(O)R^a, C(O)OR^a, C(O)NR^aR^a¹, S(O)₂NR^aR^a¹, S(O)_pR^a², CF₃, and C₃₋₆ carbocycle ~~and a 5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p~~;

R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^a¹, C(O)R^a, C(O)OR^a, C(O)NR^aR^a¹, S(O)₂NR^aR^a¹, S(O)_pR^a², CF₃, and C₃₋₆ carbocycle ~~and a 5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p~~;

R⁵, at each occurrence, is selected from C₁₋₆ alkyl substituted with 0-2 R^b, and C₁₋₄ alkyl substituted with 0-2 R^e;

R^e, at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b;

R⁶, at each occurrence, is selected from phenyl, naphthyl, C₁₋₁₀ alkyl-phenyl-C₁₋₆ alkyl-, C₃₋₁₁ cycloalkyl, C₁₋₆ alkylcarbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxy carbonyloxy-C₁₋₃ alkyl-, C₂₋₁₀ alkoxy carbonyl, C₃₋₆ cycloalkylcarbonyloxy-C₁₋₃ alkyl-, C₃₋₆

cycloalkoxycarbonyloxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxycarbonyl, phenoxy carbonyl, phenoxy carbonyloxy-C₁₋₃ alkyl-, phenyl carbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxy-C₁₋₆ alkyl carbonyloxy-C₁₋₃ alkyl-, [5-(C_{1-C5} alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl, [5-(R^a)-1,3-dioxa-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, -C₁₋₁₀ alkyl-NR^{7a}, -CH(R⁸)OC(=O)R⁹, and -CH(R⁸)OC(=O)OR⁹;

R⁷ is selected from H and C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl-, and phenyl-C₁₋₆ alkyl-;

R^{7a} is selected from H and C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl-, and phenyl-C₁₋₆ alkyl-;

R⁸ is selected from H and C₁₋₄ linear alkyl;

R⁹ is selected from H, C₁₋₆ alkyl substituted with 1-2 R^f, C₃₋₆ cycloalkyl substituted with 1-2 R^f, and phenyl substituted with 0-2 R^b;


R^f, at each occurrence, is selected from C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₁₋₅ alkoxy, and phenyl substituted with 0-2 R^b;

p, at each occurrence, is selected from 0, 1, and 2;


r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

r¹, at each occurrence, is selected from 0, 1, 2, 3, and 4.

3. (Currently amended) A compound according to Claim 2, wherein the compound is of formula IIIa or IIIb:



IIIa



IIIb

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

A is selected from -CO₂H, CH₂CO₂H, -CONHOH, -CONHOR⁵, -N(OH)CHO, and -N(OH)COR⁵;

Z is ~~absent or selected from a C₅₋₆ carboeyclic phenyl substituted with 0-3 R^b and a 5-6 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^b,~~

U^a is absent or is selected from: O, NR^{a1}, C(O), C(O)NR^{a1}, S(O)_p, and S(O)_pNR^{a1};

X^a is absent or selected from C₁₋₄ alkylene, C₂₋₄ alkenylene, and C₂₋₄ alkynylene

Y^a is absent or selected from O and NR^{a1};

Z^a is ~~selected from H, a C₅₋₆ carboeyclic pyridyl substituted with 0-3 R^c and a 5-10 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or quinolinyl substituted with 0-3 R^c;~~

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

R² is selected from Q, C₁₋₆ alkylene-Q, C₂₋₆ alkenylene-Q, C₂₋₆ alkynylene-Q, (CR^aR^{a¹})_{r¹}C(O)(CR^aR^{a¹})_{r¹}-Q, (CR^aR^{a¹})_{r¹}C(O)O(CR^aR^{a¹})_{r¹}-Q, (CR^aR^{a²})_{r¹}C(O)NR^aR^{a¹}, (CR^aR^{a²})_{r¹}C(O)NR^a(CR^aR^{a¹})_{r¹}-Q, and (CR^aR^{a¹})_{r¹}S(O)_p(CR^aR^{a¹})_{r¹}-Q;

Q is selected from H, and a C₃₋₆ carbocycle substituted with 0-3 R^d ~~and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^d~~;

R^a, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

R^{a¹}, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

R^{a²}, at each occurrence, is independently selected from C₁₋₄ alkyl, phenyl, and benzyl;

R^b, at each occurrence, is independently selected from C₁₋₄ alkyl, OR^a, Cl, F, =O, NR^aR^{a¹}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, and CF₃;

R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a¹}, C(O)R^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, and CF₃;

R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a¹}, C(O)R^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, CF₃, and phenyl;

R^5 , at each occurrence, is selected from C_{1-4} alkyl substituted with 0-2 R^b , and C_{1-4} alkyl substituted with 0-2 R^e ;

R^e , at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b ;



p , at each occurrence, is selected from 0, 1, and 2;

r , at each occurrence, is selected from 0, 1, 2, 3, and 4;

r^1 , at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

s and s^1 combine to total 2, 3, or 4.

4. (Currently amended) A compound according to Claim 3, wherein the compound is of formula IVa or IVb:



or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

Z is **absent or selected from** phenyl substituted with 0-3 R^b **and pyridyl substituted with 0-3 R^b** ;

U^a is absent or is O;

X^a is absent or is CH₂ or CH₂CH₂;

Y^a is absent or is O;

Z^a is ~~selected from H, phenyl substituted with 0-3 R^e, pyridyl substituted with 0-3 R^c, and~~
or quinolinyl substituted with 0-3 R^c;

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, or O-O group;

R¹ is selected from H, CH₃, and CH₂CH₃;

R² is selected from Q, C₁₋₆ alkylene-Q, C₂₋₆ alkynylene-Q, C(O)(CR^aR^{a¹})_r-Q,
C(O)O(CR^aR^{a¹})_r-Q, C(O)NR^a(CR^aR^{a¹})_r-Q, and S(O)_p(CR^aR^{a¹})_r-Q;

Q is selected from H, cyclopropyl substituted with 0-1 R^d, cyclobutyl substituted with 0-1 R^d, cyclopentyl substituted with 0-1 R^d, cyclohexyl substituted with 0-1 R^d, and phenyl substituted with 0-2 R^d ~~and a heteroaryl substituted with 0-3 R^d, wherein the heteroaryl is selected from pyridyl, quinolinyl, thiazolyl, furanyl, imidazolyl, and isoxazolyl;~~

R^a, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

R^{a¹}, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

R^{a²}, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

R^b , at each occurrence, is independently selected from C_{1-4} alkyl, OR^a , Cl, F, $=O$, $NR^aR^a^1$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^a^1$, $S(O)_2NR^aR^a^1$, $S(O)_pR^a^2$, and CF_3 ;

R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, $=O$, $NR^aR^a^1$, $C(O)R^a$, $C(O)NR^aR^a^1$, $S(O)_2NR^aR^a^1$, $S(O)_pR^a^2$, and CF_3 ;

R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, $=O$, $NR^aR^a^1$, $C(O)R^a$, $C(O)NR^aR^a^1$, $S(O)_2NR^aR^a^1$, $S(O)_pR^a^2$, CF_3 and phenyl;

p , at each occurrence, is selected from 0, 1, and 2;

r , at each occurrence, is selected from 0, 1, 2, and 3;

r^1 , at each occurrence, is selected from 0, 1, 2, and 3; and,

s and s^1 combine to total 2, 3, or 4.

5. (Currently amended) A compound according to Claim 2, wherein;

A is selected from $-CO_2H$, CH_2CO_2H , $-CONHOH$, $-CONHOR^5$, $-N(OH)CHO$, and $-N(OH)COR^5$;

ring B is ~~a 4-7 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, and NR^2 , provided that ring B contains other than a O-O bond piperidinyl or pyridinyl;~~

Z is ~~absent or selected from a C₅₋₆ carbocycle phenyl~~ substituted with 0-3 R^b ~~and a 5-6 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^b~~;

U^a is absent or is selected from: O, NR^{a1}, C(O), C(O)NR^{a1}, S(O)_p, and S(O)_pNR^{a1};

X^a is absent or selected from C₁₋₂ alkylene, C₂₋₄ alkenylene, and C₂₋₄ alkynylene

Y^a is absent or selected from O and NR^{a1};

Z^a is ~~selected from H, a C₅₋₆ carbocycle pyridyl~~ substituted with 0-3 R^c ~~and a 5-10 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or quinolinyl~~ substituted with 0-3 R^c;

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

R² is (CR^aR^{a1})_{r1}O(CR^aR^{a1})_{r2}-Q or (CR^aR^{a1})_{r1}NR^a(CR^aR^{a1})_{r2}-Q;

Q is selected from H, ~~and a C₃₋₆ carbocycle substituted with 0-3 R^d and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^d~~;

R^a, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

R^{a¹}, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

R^{a²}, at each occurrence, is independently selected from C₁₋₄ alkyl, phenyl and benzyl;

R^b, at each occurrence, is independently selected from C₁₋₄ alkyl, OR^a, Cl, F, =O, NR^aR^{a¹},
C(O)R^a, C(O)OR^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, and CF₃;

R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O,
NR^aR^{a¹}, C(O)R^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, and CF₃;

R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O,
NR^aR^{a¹}, C(O)R^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, CF₃ and phenyl;

R⁵, at each occurrence, is selected from C₁₋₄ alkyl substituted with 0-2 R^b, and C₁₋₄ alkyl
substituted with 0-2 R^e;

R^e, at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl
substituted with 0-2 R^b;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

r¹, at each occurrence, is selected from 0, 1, 2, 3, and 4.

6. A compound according to Claim 5, wherein;

A is -CONHOH;

ring B is ~~a 5-6 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, and NR², provided that ring B contains other than a O-O bond piperidinyl or pyridinyl;~~

Z is ~~absent or selected from~~ phenyl substituted with 0-3 R^b ~~and pyridyl substituted with 0-3 R^b~~;

U^a is absent or is O;

X^a is absent or is CH₂ or CH₂CH₂;

Y^a is absent or is O;

Z^a is ~~selected from H, phenyl substituted with 0-3 R^c, pyridyl substituted with 0-3 R^c, and~~ or quinolinyl substituted with 0-3 R^c;

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, or O-O group;

R¹ is selected from H, CH₃, and CH₂CH₃;

R² is (CR^aR^{a1})_{r1}O(CR^aR^{a1})_{r2}-Q or (CR^aR^{a1})_{r1}NR^a(CR^aR^{a1})_{r2}-Q;

Q is selected from H, cyclopropyl substituted with 0-1 R^d, cyclobutyl substituted with 0-1 R^d, cyclopentyl substituted with 0-1 R^d, cyclohexyl substituted with 0-1 R^d, and phenyl substituted with 0-2 R^d, ~~and a heteroaryl substituted with 0-3 R^d, wherein the heteroaryl is selected from pyridyl, quinolinyl, thiazolyl, furanyl, imidazolyl, and isoxazolyl;~~

R^a, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

R^{a¹}, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

R^{a²}, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

R^b, at each occurrence, is independently selected from C₁₋₄ alkyl, OR^a, Cl, F, =O, NR^aR^{a¹}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, and CF₃;

R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a¹}, C(O)R^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, and CF₃;

R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a¹}, C(O)R^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, CF₃ and phenyl;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, and 3; and,

r¹, at each occurrence, is selected from 0, 1, 2, and 3.

7. A compound according to Claim 1, wherein the compound is selected from the group:

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]-2'-(trifluoromethyl)[1,1'-biphenyl]-4-carboxamide

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-[2-(trifluoromethyl)phenoxy]benzamide

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-(3-methyl-2-pyridinyl)benzamide

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl][1,1'-biphenyl]-4-carboxamide

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-phenoxybenzamide

4-(benzyloxy)-N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]benzamide

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]-2'-methoxy[1,1'-biphenyl]-4-carboxamide

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]-2'-methyl[1,1'-biphenyl]-4-carboxamide

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-(2-methoxyphenoxy)benzamide

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-(2-methylphenoxy)benzamide

N-[(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-(3-methylphenoxy)benzamide

~~4-(5,8-dihydro-4-quinolinyl)-N-((1R,2S)-2-~~

~~[(hydroxyamino)carbonyl]cyclopentyl}benzamide~~

~~N-((1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl)-3',5'-dimethyl[1,1'-biphenyl]-4-carboxamide~~

~~N-((1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl)-6-(2-methylphenyl)nicotinamide~~

~~N-((1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl)-6-(2-methoxyphenyl)nicotinamide~~

~~(3S,4S)-N-hydroxy-1-isopropyl-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-(2,2-dimethylpropanoyl)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-(methylsulfonyl)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-1-methyl-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~tert-butyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

tert-butyl 4-[(*cis*-3-[(hydroxyamino)carbonyl] 4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)pyrrolidinyl]-1-piperidinecarboxylate

cis-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-(4-piperidinyl)-3-pyrrolidinecarboxamide

cis-1-[3-[(1,1-dimethylethoxy)carbonyl]pyrrolidinyl]-N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide

cis-N-hydroxy-1-[3-pyrrolidinyl]-3-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide

tert-butyl (3*R*,4*R*)-3-[(hydroxyamino)carbonyl] 4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate

tert-butyl (3*S*,4*R*)-3-[(hydroxyamino)carbonyl] 4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate

(3*S*,4*R*)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide

tert-butyl (3*R*,4*S*)-3-[(hydroxyamino)carbonyl] 4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate

(3*R*,4*S*)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide

N-[(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl] 4-(4-pyridinyl)benzamide

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

~~(3S,4S)-1-(1,1-dimethyl-2-propynyl)-N-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-1-(2-propynyl)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-allyl-N-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-1-propyl-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-1-(2-methyl-2-propenyl)-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-(1,1-dimethyl-2-propenyl)-N-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-1-tert-pentyl-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-1-isopentyl-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-1-neopentyl-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-buty1-N-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-(3-butenyl)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-(2-butynyl)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-(2-furylmethyl)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3R,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)tetrahydro-3-furancarboxamide~~

~~(3S,4R)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)tetrahydro-3-furancarboxamide~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-(1,3-thiazol-2-ylmethyl)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-acetyl-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-1-isobutryrl-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

~~(3S,4S)-N-hydroxy-1-(3-methylbutanoyl)-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-(cyclopropylcarbonyl)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-(cyclobutylcarbonyl)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-1-(methoxyacetyl)-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-1-(2-furoyl)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-(2-thienylcarbonyl)-3-pyrrolidinecarboxamide~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-propionyl-3-pyrrolidinecarboxamide~~

~~(3R,4S)-4-[(4-(2-butynyl)benzoyl)amino]-N-hydroxy-tetrahydro-3-furanearboxamide~~

~~N-[(1R,2S)-2-[(hydroxyamino)carbonyl]-4-oxocyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide~~

~~N-[(1R,2S,4R)-4-hydroxy-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide~~

~~N-((1R,2S,4S)-4-hydroxy-2-[(hydroxyamino)carbonyl]cyclopentyl)-4-[(2-methyl-4-quinolinyl)methoxy]benzamide~~

~~(3S,4S)-N-hydroxy-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-tetrahydro-2H-pyran-4-yl-3-pyrrolidinecarboxamide~~

~~methyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate~~

~~ethyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate~~

~~propyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate~~

~~allyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate~~

~~isopropyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate~~

~~2-propynyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate~~

~~2-butynyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-((4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate~~

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

~~3-butetyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-[(4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino]-1-pyrrolidinecarboxylate~~

~~benzyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-[(4-[(2-methyl-4-quinolinyl)methoxy]benzoyl)amino]-1-pyrrolidinecarboxylate~~

~~N-[(1R,2S)-4-(dimethylamino)-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide~~

~~(3S,4S)-4-[(4-(2-butynyloxy)benzoyl)amino]-N-hydroxy-1-isopropyl-3-pyrrolidinecarboxamide~~

~~N-[(1R,2S)-4,4-difluoro-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide~~

~~(3S,4S)-N-hydroxy-1-isopropyl-4-[(4-(2-methylphenoxy)benzoyl)amino]-3-pyrrolidinecarboxamide~~

~~cis-N-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentane carboxamide~~

~~trans-N-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentane carboxamide~~

~~(1S,2R)-N-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentane carboxamide~~

~~(1R,2S)-N-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentane carboxamide~~

cis-N-hydroxy-2-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-cyclohexanecarboxamide

trans-N-hydroxy-2-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-cyclohexanecarboxamide

trans-1-[(1,1-dimethylethyl)oxy]carbonyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide

trans-N-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide

cis-1-[(1,1-dimethylethyl)oxy]carbonyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide

cis-N-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide

(3*S*,4*R*)-1-[(1,1-dimethylethyl)oxy]carbonyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*S*)-1-[(1,1-dimethylethyl)oxy]carbonyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*S*)-N-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-[(butoxy)carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-*N*-hydroxy-1-[[[(1-methylethyl)oxy]carbonyl]-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-*N*-hydroxy-1-(methylsulfonyl)-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-3-piperidinecarboxamide

(3*S*,4*R*)-1-acetyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-benzoyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-3-piperidinecarboxamide

(3*S*,4*R*)-1-(dimethylcarbamyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-*N*-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-ethyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-propyl-3-piperidinecarboxamide

(3*S*,4*R*)-*N*-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-(cyclopropylmethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-benzyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-(2-thiazolylmethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

(3*S*,4*S*)-1-[[*(1,1*-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*R*,4*S*)-1-[[*(1,1*-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*R*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-[(2-methylpropyl)oxy]carbonyl]-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(methoxycarbonyl)-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-[(1-methylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(methylsulfonyl)-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-4-piperidinecarboxamide

(3*S*,4*S*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-benzoyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-[(pyridin-3-yl)carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(2-thiophenecarbonyl)-4-piperidinecarboxamide

(3*S*,4*S*)-1-(dimethylcarbamyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-[(2-(2-thienyl)ethyl]carbamyl]-4-piperidinecarboxamide

(3*S*,4*S*)-1-[(1,1-dimethylethyl)carbamyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

(3*S*,4*S*)-1-ethyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidin carboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-propyl-4-piperidin carboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidin carboxamide

(3*S*,4*S*)-1-cyclobutyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidin carboxamide

(3*S*,4*S*)-1-butyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidin carboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(2-methylpropyl)-4-piperidin carboxamide

(3*S*,4*S*)-1-(cyclopropylmethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidin carboxamide

(3*S*,4*S*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidin carboxamide

(3*S*,4*S*)-1-cyclopentyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidin carboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropyranyl)-4-piperidin carboxamide

(3*S*,4*S*)-1-benzyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(2-thiazolylmethyl)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(4-pyridinylmethyl)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(2-pyridinylmethyl)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(3-pyridinylmethyl)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(*trans*-3-phenyl-2-propenyl)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-phenyl-4-piperidinecarboxamide

(3*R*,4*S*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*R*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-methyl-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

(3*R*,4*S*)-1-(dimethylcarbamyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-hexyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-(2-fluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-(2,2-difluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(1-methylpropyl)-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-(1-ethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-[1-[(1,1-dimethylethyl)oxy]carbonyl]-4-tetrahydropiperidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropiperidinyl)-4-piperidinecarboxamide

(3*S*,4*S*)-1-[1-[(1,1-dimethylethyl)oxy]carbonyl]-3-tetrahydropyrrolidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(3-tetrahydropyrrolidinyl)-4-piperidinecarboxamide

(3*S*,4*S*)-1-(1,1-dimethyl-2-propynyl)-*N*-hydroxy-3-[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-(3-thiophenylmethyl)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[4-[(2-methyl-1-oxo-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[4-[(2-methyl-1-oxo-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide

(3*S*,4*S*)-1-[2-(*N,N*-dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[4-[(2-methyl-1-oxo-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-(benzenesulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-(t-butylsulfinyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(2-hydroxylethyl)-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-[2-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]ethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-(2-aminoethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-[2-(N,N-dimethylamino)ethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-[(2*S*)-2-aminopropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-1-[(2*R*)-2-amino-3-hydroxypropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-1-[(2*R*)-2-pyrrolidinyl]methyl]-4-piperidinecarboxamide

(3*S*,4*R*)-*N*-hydroxy-1-(2-hydroxylethyl)-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-(2-aminoethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*S*,4*R*)-1-cyclobutyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

(3*R*,4*R*)-*N*-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)tetrahydro-2*H*-pyran-3-carboxamide

(3*S*,4*S*)-1-tert-butyl-*N*-hydroxy-3-({4-[(2-methyl-4-quinoliny)methoxy]benzoyl}amino)-4-piperidinecarboxamide

tert-butyl 2-[(3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinoliny)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate

2-[(3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinoliny)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoic acid

methyl 2-[(3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinoliny)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate

(3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinoliny)methoxy]benzoyl}amino)-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide

(3*S*,4*S*)-1-[2-(dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-({4-[(2-methyl-4-quinoliny)methoxy]benzoyl}amino)-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

(3*S*,4*S*)-1-(1,1-dimethyl-2-propenyl)-*N*-hydroxy-3-(*{*4-[*(*2-methyl-4-quinoliny*l*)methoxy*]*benzoyl*l*}amino)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-(*{*4-[*(*2-methyl-4-quinoliny*l*)methoxy*]*benzoyl*l*}amino)-1-*tert*-pentyl-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-(*{*4-[*(*2-methyl-4-quinoliny*l*)methoxy*]*benzoyl*l*}amino)-1-(2-propynyl)-4-piperidinecarboxamide

(3*S*,4*S*)-1-allyl-*N*-hydroxy-3-(*{*4-[*(*2-methyl-4-quinoliny*l*)methoxy*]*benzoyl*l*}amino)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(1-methyl-2-propynyl)-3-(*{*4-[*(*2-methyl-4-quinoliny*l*)methoxy*]*benzoyl*l*}amino)-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-1-(1-methyl-2-propenyl)-3-(*{*4-[*(*2-methyl-4-quinoliny*l*)methoxy*]*benzoyl*l*}amino)-4-piperidinecarboxamide

***N*-(1*R*,2*S*)-4,5-dihydroxy-2-[(hydroxyamino)carbonyl]cyclohexyl-4-[*(*2-methyl-4-quinoliny*l*)methoxy*]*benzamide**

(5*S*)-*N*-hydroxy-5-(*{*4-[*(*2-methyl-4-quinoliny*l*)methoxy*]*benzoyl*l*}amino)-2-oxo-4-piperidinecarboxamide

(3*S*,4*S*)-*N*-hydroxy-3-(*{*4-[*(*2-methyl-4-quinoliny*l*)methoxy*]*benzoyl*l*}amino)-2-oxo-4-piperidinecarboxamide

(3*S*,4*S*)-3-[*{*4-(2-butyloxy)benzoyl*l*}amino*]*-*N*-hydroxy-1-isopropyl-4-piperidinecarboxamide

(3S,4S)-3-[(4-(2-butyloxy)benzoyl]amino)-N-hydroxy-4-piperidinecarboxamide

tert-butyl (3S,4S)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-1-piperidinecarboxylate

(3S,4S)-N-hydroxy-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide

tert-butyl (3S,4S)-3-({4-[(2,5-dimethylbenzyl)oxy]benzoyl}amino)-4-[(hydroxyamino)carbonyl]-1-piperidinecarboxylate

(3S,4S)-3-({4-[(2,5-dimethylbenzyl)oxy]benzoyl}amino)-N-hydroxy-4-piperidinecarboxamide

(*cis,cis*)-3-Amino-2-[[[4-(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide

(*cis,cis*)-3-Methylamino-2-[[[4-(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide

(*cis,cis*)-3-Dimethylmino-2-[[[4-(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*N*-hydroxy)cyclohexylcarboxamide

(*cis,trans*)-3-Amino-2-[[[4-(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*N*-hydroxy)cyclohexylcarboxamide

(cis,trans)-3-Dimethylmino-2-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-N-hydroxy)cyclohexylcarboxamide

(cis,trans)-3-(1-Methyl-1-ethylmino)-2-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-N-hydroxy)cyclohexylcarboxamide

(cis,trans)-3-Methylamino-2-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-N-hydroxy)cyclohexylcarboxamide

(cis,cis)-3-Hydroxy-2-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]carbonyl]amino]-N-hydroxy)cyclohexylcarboxamide

N-[cis-2-[(Hydroxyamino)carbonyl]cyclopentyl]-4-[(2-methyl-4-quinoliny)methyl]amino]benzamide

N-[cis-2-[(Hydroxyamino)carbonyl]cyclopentyl]-4-(methyl[(2-methyl-4-quinoliny)methyl]amino)benzamide

N-[cis-2-[(Hydroxyamino)carbonyl]cyclopentyl]-4-(3-phenyl-4,5-dihydro-5-isoxazolyl)benzamide

N-[cis-2-[(Hydroxyamino)carbonyl]cyclopentyl]-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide

N-[cis-2-[(Hydroxyamino)carbonyl]cyclopentyl]-4-[3-(3-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

N-*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(2-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide

N-*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-quinolinyl)-4,5-dihydro-5-isoxazolyl]benzamide

4-[3-(2,6-Dimethyl-4-pyridinyl)-4,5-dihydro-5-isoxazolyl]-*N*-*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl]benzamide

N-*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-3-methoxy-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide

3-Hydroxy-*N*-*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide

N-*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(2-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide

N-*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(4-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide

N-{4-[(hydroxyamino)carbonyl]-3-pyrrolidinyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-5-carboxamide

N-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-5-carboxamide

N-hydroxy-3-({6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthoyl}amino)-4-piperidinecarboxamide

N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-6-[(2-methyl-4-quinoliny)methoxy]-1-naphthamide

N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-6-[(2-methyl-4-quinoliny)methoxy]-2-naphthamide

N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-6-[(2-methyl-4-quinoliny)methoxy]-1,2,3,4-tetrahydro-1-isoquinolinecarboxamide

N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinoliny)methyl]-1H-benzimidazole-5-carboxamide

N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinoliny)methyl]-1H-indole-4-carboxamide

(±)-cis-N-hydroxy-2-[[4-[(2-methyl-4-quinoliny)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide

(±)-trans-N-hydroxy-2-[[4-[(2-methyl-4-quinoliny)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide

(4S,5R)-N-hydroxy-5-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-2-oxohexahydro-1H-azepine-4-carboxamide

(3S,4S)-N-hydroxy-3-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-7-oxohexahydro-1H-azepine-4-carboxamide

DOCKET NO.: PH-7121-DIV1
USSN: 10/779,539

Amendment

~~(3S,4R)-N-hydroxy-4-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-7-oxohexahydro-1*H*-azepine-3-carboxamide~~

~~(4S,5R)-N-hydroxy-5-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-7-oxohexahydro-1*H*-azepine-4-carboxamide~~

~~(2S,3R)-N-hydroxy-3-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-2-pyrrolidinecarboxamide~~

~~(2R,3R)-N-hydroxy-3-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-2-pyrrolidinecarboxamide, and~~

~~tert-butyl (2S,3R)-2-[(hydroxyamino)carbonyl]-3-((4-[(2-methyl-4-quinoliny)methoxy]benzoyl)amino)-1-pyrrolidinecarboxylate~~

or a pharmaceutically acceptable salt form thereof.

8. (Original) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt form thereof.

9. (Canceled)

10. (Withdrawn) A method of treating ~~according to Claim 9, wherein the a~~ disease or condition ~~is referred to as selected from acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate~~

~~deposition disease, cardiovascular effects, chronic fatigue syndrome, chronic obstruction pulmonary disease, coagulation, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, HIV infection, hyperoxic alveolar injury, infectious arthritis, inflammation, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pyoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, and rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, skin inflammatory diseases, solid tumor growth and tumor invasion by secondary metastases, spondylitis, stroke, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 1.~~

11. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 2 or a pharmaceutically acceptable salt form thereof.

12. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 3 or a pharmaceutically acceptable salt form thereof.

13. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 4 or a pharmaceutically acceptable salt form thereof.

14. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 5 or a pharmaceutically acceptable salt form thereof.

15. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 6 or a pharmaceutically acceptable salt form thereof.

16. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 7 or a pharmaceutically acceptable salt form thereof.

17. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 2.

18. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the

mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 3.

19. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 4.

20. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 5.

21. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 6.

22. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 7.